The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Updated survival and early translational results from Big Ten Cancer Research Consortium Study.
 
Hirva Mamdani
Consulting or Advisory Role - AstraZeneca; Tempus
Travel, Accommodations, Expenses - AstraZeneca; Caris Life Sciences; Takeda
 
Bryan J. Schneider
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Macrogenics (Inst); MedImmune (Inst); OncoMed (Inst)
 
Pashtoon Murtaza Kasi
Consulting or Advisory Role - Foundation Medicine; Ipsen (Inst); Natera; Taiho Pharmaceutical (Inst)
Research Funding - Advanced Accelerator Applications (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst)
 
Laith I. Abushahin
Honoraria - Bionest Partner
Research Funding - Celgene (Inst)
 
Thomas J. Birdas
No Relationships to Disclose
 
Kenneth Kesler
No Relationships to Disclose
 
Heather Burney
No Relationships to Disclose
 
Susan Perkins
No Relationships to Disclose
 
Shadia Ibrahim Jalal
Research Funding - Astex Pharmaceuticals; AstraZeneca/MedImmune; Tesaro